RESEARCH ARTICLE

Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction

Mallika Ghosh¹,²*, Shobha Thangada¹,²*, Oisharya Dasgupta¹,², Kamal M. Khanna³, Harold T. Yamase⁴, Michael Kashgarian⁵, Timothy Hla⁶, Linda H. Shapiro¹,²*, Fernando A. Ferrer¹,²,⁷*

¹ Center for Vascular Biology, University of Connecticut School of Medicine, Farmington, CT, United States of America, ² Department of Cell Biology, University of Connecticut School of Medicine, Farmington, CT, United States of America, ³ Department of Immunology, University of Connecticut School of Medicine, Farmington, CT, United States of America, ⁴ Department of Pathology, University of Connecticut School of Medicine, Farmington, CT, United States of America, ⁵ Department of Pathology, Yale University Cancer Research Center, New Haven, CT, United States of America, ⁶ Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America, ⁷ Section of Pediatric Urology, Children’s Hospital of Omaha, Department of Surgery, University of Nebraska School of Medicine, Omaha, NE, United States of America

☯ These authors contributed equally to this work.

*fferrer@childrensomaha.org (FAF); lshapiro@uchc.edu (LHS)

Abstract

Sphingosine Kinase-2 (Sphk2) is responsible for the production of the bioactive lipid Sphingosine-1 Phosphate, a key regulator of tissue repair. Here we address the in vivo significance of Sphingosine Kinase-2 in renal inflammation/fibrosis in response to unilateral ureteral obstruction using both genetic and pharmacological strategies. Obstructed kidneys of Sphk2⁻/⁻ mice showed reduced renal damage and diminished levels of the renal injury markers TGFβ₁ and αSMA when compared to wild type controls. We found a consistently significant increase in anti-inflammatory (M2) macrophages in obstructed Sphk2⁻/⁻ kidneys by flow cytometry and a decrease in mRNA levels of the inflammatory cytokines, MCP1, TNFα, CXCL1 and ILβ₁, suggesting an anti-inflammatory bias in the absence of Sphk2. Indeed, metabolic profiling showed that the pro-inflammatory glycolytic pathway is largely inactive in Sphk2⁻/⁻ bone marrow-derived macrophages. Furthermore, treatment with the M2-promoting cytokines IL-4 or IL-13 demonstrated that macrophages lacking Sphk2 polarized more efficiently to the M2 phenotype than wild type cells. Bone marrow transplant studies indicated that expression of Sphk2⁻/⁻ on either the hematopoietic or parenchymal cells did not fully rescue the pro-healing phenotype, confirming that both infiltrating M2-macrophages and the kidney microenvironment contribute to the damaging Sphk2 effects. Importantly, obstructed kidneys from mice treated with an Sphk2 inhibitor recapitulated findings in the genetic model. These results demonstrate that reducing Sphk2 activity by genetic or pharmacological manipulation markedly decreases inflammatory and fibrotic responses to obstruction, resulting in diminished renal injury and supporting Sphk2 as a novel driver of the pro-inflammatory macrophage phenotype.

OPEN ACCESS

Citation: Ghosh M, Thangada S, Dasgupta O, Khanna KM, Yamase HT, Kashgarian M, et al. (2018) Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. PLoS ONE 13(3): e0194053. https://doi.org/10.1371/journal.pone.0194053

Editor: David Long, UCL Institute of Child Health, UNITED KINGDOM

Received: September 17, 2017
Accepted: February 25, 2018
Published: March 8, 2018

Copyright: © 2018 Ghosh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by multi-investigator grants from National Institute of Health R01HL127449 and R01HL125186 (LHS), R01CA1689 (FF), HL67330, HL089934 and HL70694 (TH), and Scientific Research Grant, Connecticut Children’s Medical Center, Hartford, Connecticut (FF). The funders had no role in study
**Introduction**

The bioactive lipid Sphingosine-1-Phosphate (S1P) and its five receptors S1PR<sub>1-5</sub> play important roles in human health and disease. S1P has been demonstrated to participate in the regulation of numerous cellular processes such as cytoskeletal rearrangement, cell migration, angiogenesis, vascular maturation, apoptosis, inflammation and immune cell trafficking[1,2]. The majority of S1P is produced as the result of the hydrolysis of sphingomyelin to sphingosine, which is then phosphorylated to S1P by either of two closely related sphingosine kinases, Sphk1 or Sphk2. Mice harboring a combined deletion of the two kinases die in utero, while mice with a single isoform deletion are viable. Both isoforms are significantly active at baseline and it is thought that Sphk1 is primarily responsible for maintaining intracellular and circulating S1P levels. While the contribution of Sphk2 is less clear in this regard, Sphk1 activity and consequent plasma S1P levels are significantly increased in Sphk2<sup>-/-</sup> mice[3], suggesting that the Sphk2 isoform also contributes to systemic S1P levels. Significant structural homology exists between the two isoforms, but their clearly differential cellular localization and sometimes opposing functions[4,5] may also suggest distinctly different roles. While Sphk1 has historically been more intensely studied due to its prominent role in tumor cell proliferation, recent investigations have increasingly focused on understanding potentially unique functions of Sphk2.

Obstructive renal injury is the most common cause of chronic kidney disease in children and similar to ischemia reperfusion injury, when damage to the obstructed kidney occurs it is accompanied by deregulation of the immune and vascular systems. The sphingolipid signaling pathways are key modulators of various inflammatory processes[6]. Given this information, in the present study we specifically investigated the contribution of Sphk2 to inflammation-induced renal damage resulting from obstructive nephropathy utilizing the Unilateral Ureteral Obstruction (UUO) model from both genetic and pharmacological perspectives. Global Sphk2-deficient mice were significantly protected from renal inflammation, thus diminishing the ensuing injury and fibrosis. This phenomenon is recapitulated in wild type mice treated with a specific Sphk2 inhibitor (SK2i), SLP 120701[7] in agreement with recent studies showing similar reductions in renal fibrosis upon Sphk2 lack or inhibition [8,9]. However, these studies did not explore a potential inflammatory basis for these effects. In this regard, our bone marrow transplant experiments indicated that both hematopoietic and parenchymal cells contribute to the deleterious effects of Sphk2 in obstructive injury. Further investigation demonstrated that either deletion or inhibition of Sphk2 protects the kidney from injury in large part by promoting macrophage polarization to the M2 phenotype and identifies Sphk2 as a mediator of macrophage specification and a critical regulator of inflammatory injury. Furthermore, we propose that pharmacologic inhibition of Sphk2 results in a defined, predictable and favorable outcome and that Sphk2 is a viable therapeutic target in the treatment of obstructive renal injury and potentially, unresolved inflammation of any etiology.

**Materials and methods**

**Mice**

The experiments were performed on 6–8 week old male C57/B6 (wild type) and Sphk2<sup>-/-</sup> mice. All animals were given humane care using protocols approved by the institutional Animal Care Committee.

**Euthanasia**

Mice were sacrificed by CO2 narcosis followed by cervical dislocation.
**Sphk2 inhibitor (SK2i, SLP 120701) model**

Male, 6–8 weeks old C57BL/6 WT mice were treated with SK2i inhibitor (3mg/kg) or vehicle control, daily by i.p three days prior to and following the UUO surgery (6 days total). SK2i (SLP 120701, formerly SKX002411) was a kind gift from SphynKx Therapeutics, Charlotteville, VA[7]. Control group received 2% Cyclodextrin (sigma) in which the drug was prepared.

**UUO model**

The general procedure of the UUO model has been well described[10]. Briefly, 6–8 weeks old WT and Sphk2\(^{-/-}\) mice were anesthetized using Isofluorane gas and complete ureteral obstruction was performed by ligating left ureter through a posterior flank incision. In the preliminary studies, we have noticed that at 24 hours of UUO, glomerular and tubulointerstitial morphologies were intact and by 72 hours of post-obstruction, renal damage was obvious and limited to tubular atrophy and widened interstitial spaces accompanied by inflammatory cell infiltration. In the present study, mice (n = 6) were sacrificed at 1, 3, 5 and 7 days (for the genetic model) and 3 and 7 days (for inhibitor model), after the obstruction surgery. The contralateral kidney served as an internal control, is comparable to sham operated kidney.

**Renal pathology and renal injury scoring**

Renal tubulointerstitial injury evaluated semi-quantitatively by a renal pathologist in WT, Sphk2\(^{-/-}\), SK2i and vehicle treated mice using H & E and PAS stained slides. Briefly, multiple tubulointerstitial fields were randomly selected and evaluated for tubulointerstitial injury based on tubular dilatation, tubular cell vascularization, tubular atrophy, proximal tubule brush border, cortical thickening, interstitial infiltrates, interstitial edema and interstitial fibrosis as described before [11] on a scale of 0–5 (0- least injury and 5—extensive injury).

**Immunohistochemistry (IHC)**

Hematoxylin and eosin, Masson’s trichrome, TGF\(\beta\) and \(\alpha\)-SMA staining performed on 5-\(\mu\)m thick paraffin sections of control and obstructed kidney as described earlier [12]. Ten consecutive fields were examined using Zeiss bright field microscope (20X objective).

**Western blot**

Proteins extracted in RIPA buffer from kidney tissues were used for western blotting for TGF\(\beta\)1 (Santa Cruz), \(\alpha\)-SMA and Sphk2 (Abcam) as described earlier [12].

In vitro differentiation of Bone marrow derived macrophages. Bone marrow cells isolated from WT and Sphk2\(^{-/-}\) mice were differentiated into macrophages, in medium containing Macrophage colony stimulating growth factor (20ng/ml-MCSF) [13] and stimulated either with IL4 or IL13 to further differentiate into M2 phenotype [14].

**Flow cytometry**

Kidney tissues were harvested and digested with Collagenase1 (Gibco) (50\(\mu\)g/ml), to isolate single cells. 2X10\(^6\) viable cells were stained with specific markers to exclude T and B Lymphocytes to analyze M2 (CD11b\(^+\), F4/80\(^+\), CD206\(^+\)) in CD45\(^+\) cells [15–17].

**RNA isolation and qRT-PCR analysis**

Total RNA was extracted from non-obstructed and obstructed kidneys of WT, Sphk2\(^{-/-}\) and SK2i treated mice and real time PCR was performed as described earlier [12].
increase in mRNA expression was normalized to GAPDH and analyzed using RQ manager and Data Assist software.

**Bone marrow transplant experiments**

For bone marrow transplant (BMT) experiments recipient wild type mice (CD45.2, 8–10 weeks) were subjected to whole body irradiation from a $^{137}$Cs radiation source (Gamma cell-40) with a total dose of 10Gy for 10 minutes and were treated with neomycin in the drinking water. Donor bone marrow cells were prepared from 6–8 week old WT and Sphk2$^{-/-}$ mice (CD45.2) and 5X10$^6$ cells were injected per mouse via the lateral tail vein immediately after the whole body irradiation of recipient mice. Engraftments were confirmed by flow cytometry analysis of circulating leukocytes pre- and post-transplant. Bone marrow transplanted chimeric mice were allowed to recover for 8 weeks before UUO. Kidneys were harvested at 7 days after surgery.

**Cellular bioenergetics-seahorse analysis**

As described previously [18] bone marrow derived macrophages from WT and Sphk2$^{-/-}$ were seeded into each well (80,000 cells/well) of Seahorse Bioscience (Billerica, MA) tissue culture plate and incubated overnight at 37°C. Before analysis cells were washed twice with glucose free DMEM assay medium supplemented with glutamine and incubated for 1 hour at 37°C without CO2. Measurements of glycolytic rate and glycolytic capacity were determined by recording extracellular acidification rate (ECAR, milli pH/min) on a Seahorse Bioscience XF96 Extracellular Flux Analyzer. The injection of glucose was used to measure glycolytic rate (final concentration 25mM), the injection of oligomycin (final concentration 2.5 μM) was used to measure glycolytic capacity and injection of 2-deoxyglucose (2DG) was used to blunt glycolysis (final concentration 20mM). Background from cell free wells was subtracted. N = 6 replicates per treatment and experiment was repeated 2 times.

**S1P measurement from plasma samples**

Plasma samples were prepared from WT, Sphk2$^{-/-}$ and SK2i treated mice for S1P measurement. Samples for S1P measurement were submitted to Lipidomic Core Mass Spectrometry Lab, Medical University of South Carolina, Charleston, South Carolina. Analysis was performed by Liquid Chromatography- ESI Mass Spectrometry (LC-MS) using triple quadrupole mass spectrometer coupled to a Shimadzu LC-20AD LC system as described earlier [3].

**Statistical analysis**

All experiments were conducted at least two times using 6 animals in each group. Data presented in graphs represent the means ± SEM for each group. Comparison of 2 groups was performed using an unpaired, 2 tailed t test. Statistical analyses were performed using GraphPad Prism (GraphPad Software Inc.). P values, *P* < 0.05, **P** < 0.01 and ***P*** < 0.001 are considered as statistically significant.

**Results**

**Obstruction-induced renal injury is diminished in Sphk2$^{-/-}$ mice**

In the kidney both Sphk1 and 2 are expressed throughout development, predominantly in the metanephric mesenchyme where expression levels increase through maturity. Sphk2$^{-/-}$ mice are phenotypically normal and we observed no remarkable differences in baseline renal histology by light or electron microscopy between wild type and Sphk2$^{-/-}$ mice. Flow cytometry studies also revealed that basal immune cell profiles of bone marrow cells were similar between the
genotypes, ensuring that any differences observed going forward are not likely due to developmental defects in the absence of Sphk2 (S1A Fig). Permanent unilateral ureteral obstruction was performed on WT and Sphk2−/− mice and both kidneys were harvested at the peak of the early and late inflammatory responses, 3 and 5 days post-surgery. Evaluation of Sphk2 expression post obstruction revealed an increase in Sphk2 protein levels in the obstructed kidney compared to non-obstructed control (S1B Fig). Hematoxylin and Eosin or Periodic acid–Schiff stained renal sections (Fig 1A and 1B) were evaluated by two independent experienced renal pathologists in a blinded manner. Assessment of renal injury was based on the degree of interstitial infiltration, cortical thickening, tubular dilatation and proximal tubule brush border integrity at day 3 on a scale of increasing damage from 0–5 based on previously published studies[11,19–21] (Fig 1C). Obstructed kidneys of Sphk2−/− mice exhibited less structural alteration when compared to WT mice as evidenced by reduced tubular dilation, epithelial cell sloughing and basement membrane thickening. There were no remarkable histological changes observed in either non-obstructed or sham operated kidneys, suggesting that Sphk2 deficiency protects kidneys from tissue injury resulting from UUO.

**TGFβ1 expression levels are diminished in Sphk2−/− mice**

Ureteral obstruction results in increased urinary pressure in the renal tubules leading to tubular dilation and damage. Tissue injury promotes the activation of resident macrophages,
progression to a pro-fibrotic phenotype, increased deposition of extracellular matrix proteins, a robust inflammatory response and ultimately, progressive renal disease. We initially assessed protein levels of pro-fibrotic TGF-β1 as a hallmark of this fibrotic progression [22,23] and found that indeed, tubulointerstitial expression of TGF-β1 progressively increased in obstructed kidneys from day 3 to day 5 post-obstruction in animals of both genotypes. However, this increase was significantly greater in WT mice when compared to Sphk2−/− mice as confirmed by IHC and western blot analysis (Fig 2A–2C).

αSmooth muscle actin levels are reduced in Sphk2−/− mice

TGFβ1 promotes the pathogenesis of renal interstitial fibrosis [24] and is characterized by de novo expression of α-SMA. Immunohistochemical staining for α-SMA demonstrated that the expression of interstitial α-SMA gradually increased over time in obstructed kidneys from both groups, but expression was substantially higher in WT as compared to Sphk2−/− mice. Similar results were obtained by western blot analysis of protein levels of α-SMA (Fig 3A–3C) in whole kidney lysates, supporting reduced myofibroblast transition and disease progression in the absence of Sphk2 following UUO.

Macrophage profiles are altered in obstructed kidneys of Sphk2−/− mice

Tissue damage resulting from ureteral obstruction signals a potent inflammatory response initiated by heterogeneous subsets of both tissue-resident immune cells and circulating...

Fig 2. TGFβ1 expression is diminished in Sphk2−/− mice compared to WT. TGFβ1 expression significantly increased in obstructed kidneys than in non-obstructed kidneys (N = 6). (A) Representative photomicrographs show immunohistochemical staining for TGFβ1 in WT mice (top panel) and Sphk2−/− (bottom panel) at 3 & 5 days after UUO in non-obstructed (NO) and obstructed (O) kidneys. (B, C) Western blot analysis of TGFβ1 in WT and Sphk2−/− mice at 1, 3 & 5 days and protein bands quantified using Image J and normalized to GAPDH. Results from contralateral non-obstructed kidney were comparable to sham operated kidneys. Experiments were repeated at least two times with N = 6 each time. WT vs Sphk2−/− at 3 day (**p<0.05); WT vs Sphk2−/− at 5 day post ligation (***p<0.01). Original magnification; 20x objective. Scale bar; 50μm.

https://doi.org/10.1371/journal.pone.0194053.g002
inflammatory cells infiltrating at the site of injury. Phenotypically distinct populations of macrophages cooperate to initially clear the wound of dead cell debris and to orchestrate the ongoing inflammatory response (pro-inflammatory or M1 macrophages) and a second group that serves to promote healing, revascularization and resolve inflammation (pro-healing or M2 macrophages). The correct balance of these subpopulations and their expressed cytokines is critical to wound healing and resolution. We tracked potential effects of lack of Sphk2 on the profiles of kidney-resident macrophages from WT and Sphk2−/− mice subjected to UUO for 3 days by flow cytometry (S3A Fig). Infiltrating macrophages at day 3 of obstruction in both WT and Sphk2−/− mice were increased in obstructed kidneys compared to non-obstructed and sham kidneys (Fig 4A, CD11b+/F4/80+/CD11c− negatively selected for CD11c+ dendritic cells). Further analysis illustrated that the macrophage population in Sphk2−/− obstructed kidneys showed a consistent 10–15% increase in cells expressing high levels of CD206, a marker of the pro-healing M2 macrophage phenotype (CD11b+ F4/80+ CD206+, Fig 4B and 4C). These results indicate that the reduction in renal injury and reduced proinflammatory cytokine levels we observe in the absence of Sphk2 may be due to a bias toward M2 macrophage polarization.

Skewed macrophage profiles would be expected to result in altered cytokine profiles in WT vs Sphk2−/− obstructed kidneys and contribute to differences in healing. qRT-PCR of total kidney RNA isolated at 3 day post-obstruction indicated that expression levels of the proinflammatory cytokines, IL-1β and TNFα were significantly lower in Sphk2−/− kidneys as compared to
the WT group (Fig 4D). These results suggest that Sphk2 contributes to inflammatory processes following UUO, perhaps at the level of macrophage polarization or subset infiltration to promote increased injury and a pro-inflammatory environment.

**Bone marrow-derived macrophages from Sphk2−/− mice are preferentially polarized toward the M2 phenotype**

To determine if the lack of Sphk2 predisposes a cell-intrinsic M2 polarization, we cultured bone marrow derived macrophages (BMDM) from WT and Sphk2−/− mice in the presence of MCSF and M2-promoting IL-4 or IL-13 cytokines. Phenotypic analysis of cells by flow cytometry after 24 hours of cytokine stimulation indicated increased percentages of M2 macrophages (CD11b+ F4/80+ CD206+) in the Sphk2−/− cultures compared to WT under identical cytokine concentrations (Fig 5A and 5B), which was accompanied by increase in mRNA levels of M2 markers Arg-1 and Ym-1 (Fig 5C). These results suggest that deficiency of Sphk2 promotes the
pro-healing M2 macrophage differentiation program, contributing to attenuated renal damage in response to ureteral obstruction.

Pro-inflammatory M1 macrophages undergo a metabolic switch toward increased glycolysis and reduced oxidative phosphorylation [18]. Altered metabolism is not only a characteristic of polarized macrophage subsets but is also a prerequisite for proper polarization and inflammatory regulation. Inhibition of glycolysis or oxidative phosphorylation has been demonstrated to impair M1 or M2 activation respectively [25], suggesting that the macrophage
Sphk2 in macrophage polarization and renal inflammation

metabolic profile is indicative of polarization status and inflammatory potential. We determined the glycolytic rate of WT and Sphk2<sup>-/-</sup> BMDMs by assessing the extracellular acidification rate (ECAR) using the Seahorse XF analyzer [18]. The addition of glucose significantly increased the glycolytic rate in WT BMDM, which was further enhanced upon addition of the glycolytic driver Oligomycin and strongly decreased upon inhibition of glucose hexokinase with 2 deoxyglucose (2DG). However, this pattern was not evident in Sphk2<sup>-/-</sup> cells indicating that the glycolytic pathway is largely inactive in the absence of Sphk2 (Fig 5D). Therefore, these results imply that the increase in M2 macrophages in Sphk2<sup>-/-</sup> mice may be due to impaired macrophage metabolism and that Sphk2 may regulate the glycolytic pathway.

An Sphk2 inhibitor diminishes renal injury

While genetic ablation is invaluable in analyzing the contribution of a particular gene to a biological process, the ultimate goal is to reproduce the favorable outcome pharmacologically. We obtained a Sphk2 inhibitor SLP120701 (SK2i) with characterized potency and specificity developed by SphynKx Therapeutics [3,7,26]. Administration of the SK2i to WT mice resulted in diminished Sphk2 protein expression 5 days post obstruction (S2A Fig) along with a substantial increase in plasma S1P levels that mimicked the phenotype of Sphk2<sup>-/-</sup> mice, indicative of a systemic effect (S2B Fig) and recapitulating the Sphk1-dependent elevation of circulating S1P levels as previously published [3]. Importantly, treatment of Sphk2<sup>-/-</sup> mice with the SK2i showed no effect on plasma S1P levels, verifying that the inhibitor specifically targets Sphk2. Renal histopathology was evaluated in mice treated with the inhibitor or vehicle controls at 3 days post UUO surgery. Similar to results obtained from the Sphk2<sup>-/-</sup> mice, SK2i treated mice showed improved histology with diminished renal injury, minimal inflammatory interstitial infiltrates, cortical thickening and tubular dilatation and intact proximal tubule brush borders (Fig 6A–6C). Further investigation demonstrated that protein levels of αSMA (Fig 6D and 6E), Vimentin and Fibronectin (Fig 7) were significantly lower in the Sphk2<sup>-/-</sup> and SK2i treated group while the overall increase in mRNA expression of the proinflammatory cytokines IL-β1,  

Fig 6. Sphk2 inhibitor treatment diminishes renal injury. 6–8 week old WT mice were treated with the Sphk2 inhibitor (SK2i) at 3mg/kg. Renal injury was assessed in H&E stain (A), PAS stain (B) and scored (C). Myofibroblast infiltration indicated by protein levels of αSMA is significantly lower in SK2i treated mice (D), protein bands quantified using Image J and normalized to GAPDH (E). **p<0.01; *p<0.05. N = 6. Experiments repeated at least two times with N = 6 each time. Original magnification; 20x objective. Scale bar; 50μm. 

https://doi.org/10.1371/journal.pone.0194053.g006
MCP-1, TNFα and CXCL1 following obstruction was significantly attenuated by SK2i treatment (Fig 8A). Finally, a higher percentage of the total kidney cells isolated from SK2i-treated mice at 3 days post-surgery were macrophages (CD11b+ F4/80+, Fig 7B and 7C) and a higher percentage of these displayed the pro-healing M2 phenotype (F4/80+ CD11b+ CD206+, Fig 8B).
and 8C). Therefore, specific inhibition of Sphk2 by this SK2i recapitulates the beneficial effects of Sphk2 deletion, supporting Sphk2 as a viable therapeutic target for mitigating renal injury.

Renal fibrosis is diminished in SK2i treated mice

Renal damage from injury and inflammation is often followed by irreparable scarring and fibrosis resulting in permanently compromised renal function. To determine if the improved structural and inflammatory outcomes observed at the early 3-day, pro-inflammatory phase translates to improved renal health long term, we evaluated renal fibrosis in mice at the fibrotic phase 7 days post-obstruction. Indeed, trichrome staining of kidney sections indicated increased levels of collagen deposition (indicative of fibrosis, blue color) in WT as compared to Sphk2−/− mice (Fig 9A and 9B). Similarly, treatment with the SK2i significantly decreased the fibrotic area in WT kidneys as compared to vehicle treated samples at 7 days post obstruction (Fig 9C and 9D). Therefore, the protective effects of Sphk2 deficiency at early stages of injury serve to reduce fibrosis long term and preserve renal integrity.
Both hematopoietic cells and the kidney parenchyma contribute to protection due to Sphk2 deletion

While our earlier in vitro studies demonstrating the pro-M2 bias of isolated Sphk2−/− macrophages suggest that this effect is cell intrinsic, it is possible that the Sphk2 expressed in the kidney parenchyma also influences renal damage. To directly address this possibility, we performed bone marrow transplant of irradiated recipient WT and Sphk2−/− mice with bone marrow from either WT or Sphk2−/− mice. Transplant efficiency and consistency among groups was confirmed by analysis of circulating leukocyte subsets repopulating the peripheral blood by flow cytometry after 6 weeks (S3B Fig); the ureters of chimeric mice obstructed eight weeks after engraftment and kidneys were harvested 7 days post-obstruction. Trichrome staining of the renal tissue indicated that the fibrotic area was maximal in wild type mice receiving wild type cells (both kidney parenchyma and hematopoietic cells are WT) and lowest in Sphk2−/− mice receiving Sphk2−/− transplants (both parenchymal and hematopoietic cells Sphk2−/−, Fig 10A and 10B). Importantly, fibrosis in WT mice receiving Sphk2−/− bone marrow (kidney parenchyma WT and Sphk2−/− hematopoietic cells) and the reverse combination, Sphk2−/− mice receiving WT bone marrow cells (kidney parenchyma Sphk2−/− and WT hematopoietic cells) were both significantly lower than WT mice receiving WT cells. Taken together, these results suggest that Sphk2 expression on the kidney parenchymal as well as the hematopoietic cells both contribute to drive the pro-inflammatory phenotype in WT mice, but the lack of Sphk2 expression in either tissue is sufficient to significantly reduce renal fibrosis.

Discussion

To date, Sphk1 has been the most actively investigated of the two sphingosine kinases and has generally been associated with pro-survival and anti-apoptotic functions. In studies

![Fig 9. Diminished renal fibrosis in Sphk2−/− and SK2i treated mice. Sphk2−/− mice and WT treated with SK2i were subjected to UUO for 7 days with appropriate control groups. Masson’s Trichrome staining indicates reduced renal fibrosis after 7 days of obstruction in Sphk2−/− (A&B) and SK2i treated mice (C&D) compared non-obstructed controls and quantitated by Image J. N = 6. (Data represents average of 3 experiments, n = 3/experiment). **p<0.01). Original magnification; 20x objective. Scale bar; 50μm.](https://doi.org/10.1371/journal.pone.0194053.g009)
manipulating levels in vivo, Sphk1 was shown to be renoprotective, primarily through its generation of S1P and subsequent activation of one of its five receptors, S1PR1 [27,28]. Paradoxically, Sphk1 is upregulated in a variety of inflammatory kidney diseases [5,29], but it is believed that increased inflammatory Sphk1 levels reflect a compensatory response to damage rather than a pro-inflammatory role for the enzyme. Alternatively, the functional effects of Sphk2 appear to be essentially the opposite of those attributed to Sphk1, as illustrated by studies wherein the genetic absence of Sphk2 is protective in ischemia-reperfusion injury of the kidney [30] and liver [31] by diminishing cell cycle arrest and apoptosis [4]. In addition, pharmacological inhibition of Sphk2 results in anti-inflammatory effects in a number of murine

![Fig 10. Sphk2 in both immune cells and kidney microenvironment contribute to renal fibrosis.](https://doi.org/10.1371/journal.pone.0194053.g010)

(A). Recipient wild-type and Sphk2<sup>−/−</sup> mice were irradiated and injected with 1 × 10<sup>6</sup> bone marrow cells obtained from WT or Sphk2<sup>−/−</sup> mice by tail vein. 8 weeks after engraftment mice were subjected to UUO for 7 days and trichrome staining performed on kidney sections. Image J quantification (B) indicates that WT mice receiving WT cells have the highest degree of renal fibrosis, followed by Sphk2<sup>−/−</sup> recipients receiving WT cells and WT mice receiving Sphk2<sup>−/−</sup> bone marrow. Sphk2<sup>−/−</sup> mice receiving Sphk2<sup>−/−</sup> transplanted cells had the least fibrosis. N = 4/genotype. *p<0.01; † p<0.05. Original magnification; 20x objective. Scale bar; 50μm.
disease models including ulcerative colitis [32], Crohn’s disease [33] and inflammatory arthritis [34], implying that reduced Sphk2 activity attenuates inflammation and injury in agreement with our findings.

Importantly, while the majority of studies support a role for Sphk2 as a pro-inflammatory molecule, the genetic ablation of Sphk2 also triggers a compensatory increase in the activity of Sphk1 and subsequent elevation of circulating S1P levels, raising the real possibility that the beneficial effects of Sphk2 inhibition are largely due to amplified S1P activity [35]. Confounding these findings is the fact that in arthritis models, genetic deletion of Sphk2 did not recapitulate the beneficial effects achieved by pharmacologic inhibition [34,36,37]. This discrepancy might suggest that the inhibitor used in these studies affects other molecules or pathways. Alternatively, this may indicate that that the Sphk2 protein has additional functions that are independent of its kinase activity and are lost only when the protein is completely absent. The current study is an effort to clarify these inconsistencies and further explore the potential of Sphk2 as a therapeutic target in treatment of renal injury.

Our current study proposes Sphk2 as a catalyst of injury-induced inflammation, as both its inhibition and genetic ablation clearly reduces key aspects of inflammation in response to UUO, including expression of critical pro-inflammatory and fibrogenic cytokines [38]. Because cytokines produced by infiltrating inflammatory macrophages contribute to ongoing inflammation and the progression of fibrosis, it is possible that the overall dampening of pro-inflammatory signals in the kidney environment in the absence of Sphk2 activity may underlie the diminished fibrosis. Similarly, the effective rescue of the protective phenotype by Sphk2−/− bone marrow in WT mice argues that the infiltrating hematopoietic cells contribute significantly to pro-healing phenotype, in agreement with published studies demonstrating a universal role for bone marrow-derived cells in promoting kidney fibrosis [39]. Alternatively, we show a higher proportion of M2 macrophages in obstructed kidneys of Sphk2−/− mice and propose that this M2-bias also promotes the protective outcome. While it is clear that dys-regulation of either arm of the healing process generates unremitting inflammation and/or maladaptive repair leading to tissue-destructive fibrosis, studies in which the balance of macrophage populations was adjusted to favor the reparative pro-healing M2 phenotype largely report improved tissue repair [40–52]. However, other studies imply that sustained activation or prolonged recruitment of M2 populations may also contribute to pathological fibrosis by producing important pro-fibrotic mediators such as TGF-β1 [53]. In the kidney, deletion or inhibition of various M1 stimuli in UUO and other renal injury models lead to an increase in M2 macrophages and generally reduced destruction and fibrosis [40–49], in agreement with our results. Similarly, an M2-bias lead to improvement [50–52] or impairment [54] of fibrosis in coronary injury models, while exacerbated renal [55] and pulmonary fibrosis [56,57] in the presence of an M2-bias has been reported; clearly these processes are mediated by mechanisms far more complex than the balance of macrophage subsets [58,59]. Future studies focusing specifically on questions such as differential or tissue-specific recruitment of various and additional novel macrophage subsets will undoubtedly clarify these issues.

The mechanisms guiding the ultimate phenotype of infiltrating macrophages, the rules that orchestrate the various interrelated phases or the complete spectrum of macrophage subsets remain unclear [58–61]. Our findings are consistent with observations that S1P itself can stimulate a significant M2 polarization via S1P-induced secretion of the M2-promoting cytokines IL-4 and IL-13 [62,63]. Alternatively, an S1P-dependent macrophage polarization toward the M1 phenotype in an Sphk2-deficient tumor xenograft model has been reported [64]. These paradoxical findings regarding S1P-dependent polarization likely reflect differences in the cytokines induced by S1P in the tumor microenvironment vs. isolated macrophages, but raise the possibility that the elevated plasma S1P levels in Sphk2−/− mice are responsible for the
differential polarization of macrophages in the kidney in our study. However, we observe a similarly skewed M2 polarization of Sphk2−/− macrophages in vitro even in the presence of high concentrations of IL-4 and IL-13, suggesting our phenotype does not rely on signaling via S1P to produce these M2 cytokines, and thus is S1P-independent. Recently, immunometabolism, or the metabolic reprogramming of cells in response to immune stimuli, has been shown to link receptor-mediated immune signal transduction to metabolic pathways that determine the lineage fate and support the unique functions of immune cell subsets (reviewed in refs [65–68]). Rapidly activated, highly proliferative cells such as pro-inflammatory M1 macrophages and effector T cells rely on glycolytic, amino acid metabolic, fatty acid synthetic and the pentose phosphate pathways to produce the energy and synthetic intermediates necessary for their stimulatory functions. Alternatively, tolerogenic/anti-inflammatory immune signals stimulate fatty acid oxidation, the TCA cycle and the arginase pathway to support functions of the M2 macrophages, Treg cells and memory CD8+ cells [68]. Inhibition or dysregulation of many of the steps of these pathways or subsequent regulatory pathways impairs polarization [40,44,50,69,70]. We show that Sphk2 is a novel regulator of macrophage polarization and that Sphk2−/− macrophages have severely impaired glycolytic activity, which might be responsible for the M2 bias. Furthermore, this intrinsic bias supports a role for Sphk2 as a fundamental inflammatory regulator that specifies the pro-inflammatory macrophage gene expression program and a potential target for ameliorating inflammatory fibrosis of any cause. Investigation into the novel or existing metabolic processes regulated by Sphk2, the mechanisms of this regulation and the potential to identify novel therapeutic immunometabolic targets is our current research focus.

Our results from bone marrow transplant experiments support a role for the kidney parenchyma in the Sphk2-mediated inflammatory response. Interestingly, in support of this data and a metabolic basis for Sphk2-mediated renal injury, investigations using the IRI model of CKD demonstrated that proximal tubule epithelial cells also undergo a metabolic switch to glycolysis early after injury that eventually reverts to allow recovery in normal tubular cells [71,72]. However, a percentage of cells fail to undergo the metabolic reversal, becoming progressively more atrophic with increased mitochondrial loss, expression of glycolytic enzymes and other indicators of unchecked glycolysis. Furthermore, therapeutic reversal of fibrosis has been attributed to inhibition of metabolic pathways, including lipid metabolism and glycolysis [73]. When taken in the context of our results regarding the decreased glycolytic potential in Sphk2-null macrophages, it is logical to postulate this phenotype extends to the proximal tubule cells. In this case, Sphk2 expression would trigger and sustain the glycolytic switch in tubular epithelium as well, promoting an adverse metabolic fate, development of atrophy and increased fibrosis contributing to the renal pathology following renal injury. Experiments are underway to investigate this intriguing possibility.

Finally, two recent studies investigated Sphk2 in renal injury by manipulating Sphk2 levels or activity in the UUO model [9] or chemical and ischemic renal injury models [8] whose results strongly support our findings that Sphk2 exacerbates renal fibrosis. While these studies had a similar focus, they each assessed response to injury at different time points post injury (3 days [this study], 7 d [9] and 14 d [8]) which logically would result in different conclusions regarding underlying mechanism, since the healing process includes the highly temporally orchestrated regulation of inflammation, fibrosis and resolution [48,74–76]. In the current study we investigated injury at 3d, the early, pro-inflammatory phase of the response that is primarily mediated by infiltrating monocytes and pro-inflammatory M1 macrophages that function to clear cell debris and call in more inflammatory cells in preparation for the M2 or pro-healing phase at 5d. We determined that at 3d, macrophage profiles in the Sphk2−/− kidneys are skewed toward the pro-healing M2 population, suggesting a role for Sphk2 in macrophage polarization to promote inflammation and fibrosis. In agreement with our findings,
Schwalm et al. [9] observed reductions in inflammation, pro-fibrotic signaling and fibrosis at the fibrotic phase, 7 days post-obstruction, upon Sphk2 deletion. Increased tissue sphingosine levels in the absence of Sphk2 led to the hypothesis that the lack of Sphk2 caused a buildup of its substrate sphingosine, leading to SMAD7 activation, decreased activation of the TGFβ/Smad2/Smad3 pathway and subsequent reduced expression of the fibrotic proteins that are critical to fibrotic repair at this phase of inflammation [9]. Finally, Bajwa et al assessed the late, 14d post-injury response and determined that the protective effects of Sphk2 loss persisted during this longer-term progression to chronic kidney disease. These investigators correlated decreased fibrosis in the absence of Sphk2 with increases in CD4+ T cell-derived IFN-γ and the IFN-γ-responsive chemokines Cxcl9 and Cxcl10. Their findings associating T cells with reduced fibrosis are in accord with deployment of the adaptive immune response following the inflammatory and fibrotic phases. Paradoxically, IFN-γ and related factors are generally considered to be pro-inflammatory, pro-fibrotic and toxic when present at early time points (reviewed in ref [77]) where IFN-γ promotes the prototypic M1, pro-inflammatory phenotype [59], suggesting that the high IFN-γ levels at later time points serve to decrease inflammation and fibrosis. Therefore, while these studies appear to be similar on the surface, their focus on very different responses further supports the utility of Sphk2 as a therapeutic target in multiple phases during the response to sterile injury.

Collectively, we show that results in genetically deficient animals are recapitulated by a novel pharmacologic inhibitor, thus implicating Sphk2 as a viable target in ameliorating obstruction-induced renal injury. By preferentially polarizing reparative M2 macrophages, lack or inhibition of Sphk2 results in diminished expression of inflammatory cytokines and reduced fibrosis at the site of injury. While aspects of the S1P signaling pathway have been well studied in the setting of renal injury, our findings, particularly as they relate to macrophage polarization, suggest that Sphk2 may play a role independent of S1P in determining macrophage phenotypic fate. These findings may have applicability to pathologies in numerous tissues that involve wound repair in response to tissue damage or injury. Moreover, further investigation into potential alternate Sphk2-dependent pathways or substrates will provide valuable clues to mechanisms responsible for immune cell-mediated regulation of inflammation and healing. Finally, these studies support the further investigation of Sphk2 inhibitors as novel therapies for modulating inflammatory injury and potentially, chronic inflammatory conditions.

Disclosures
All animal experiments in this study were reviewed and approved by Animal Care Committee at UCONN Health. All the authors do not have any conflict of interest.

Supporting information
S1 Fig. (A) Basal immune profile of bone marrow cells in WT and Sphk2−/− mice. Flow cytometry studies revealed that basal immune cell profiles of peripheral blood, bone marrow, kidney, spleen and lymph nodes were similar between the genotypes. We have shown immune profile of bone marrow cells in the figure. (B) Sphk2 protein expression is upregulated following renal injury. 6–8 week old WT mice were subjected to UUO and Sphk2 protein levels were assessed in kidney lysates over time.

S2 Fig. SK2i treatment reduces Sphk2 protein expression with elevated plasma S1P levels and reduces renal injury in WT mice. (A). Diminished renal expression of Sphk2 in WT
mice treated with SK2i (3mg/kg) following UUO. (B). Circulating S1P levels as analyzed by Liquid Chromatography- ESI Mass Spectrometry (LC-MS), were significantly increased in SK2i treated mice and Sphk2\(^{-/-}\) mice compared to WT and vehicle treated group, n = 6.

(TIF)

S3 Fig. Pseudo-color plots of gating strategy used in kidney cells for in vivo studies or bone marrow derived macrophages for in vitro studies. (A). Figure shows sequential gating to obtain a CD45\(^+\) hematopoietic cell population. T and B Lymphocytes, Ly6G\(^+\) neutrophils and natural killer cells were gated out of the live cell population and the remaining CD45\(^+\) cells were analyzed for CD11b\(^+\) F4/80\(^+\) CD206\(^+\).

(B). Flow cytometry analysis of leukocytes obtained from peripheral blood of indicated groups of mice 6 weeks post-transplant. %CD45 cells confirmed transplant efficiency and consistency among experimental groups.

(TIF)

Acknowledgments

We thank Kevin Lynch and Andy Bolt from SphynKx Therapeutics, Charlottesville, VA for providing the purified Sphk2 inhibitor SLP 120701. We also thank Research Histology and Evan Jellison from Flow cytometry core facilities at UConn Health, for providing timely services.

Author Contributions

Conceptualization: Mallika Ghosh, Shobha Thangada, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Data curation: Mallika Ghosh, Shobha Thangada, Kamal M. Khanna, Harold T. Yamase, Michael Kashgarian, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Formal analysis: Mallika Ghosh, Shobha Thangada, Oisharya Dasgupta, Kamal M. Khanna, Harold T. Yamase, Michael Kashgarian, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Funding acquisition: Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Investigation: Mallika Ghosh, Shobha Thangada, Kamal M. Khanna, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Methodology: Mallika Ghosh, Shobha Thangada, Kamal M. Khanna, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Project administration: Mallika Ghosh, Shobha Thangada, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Resources: Mallika Ghosh, Shobha Thangada, Kamal M. Khanna, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Software: Mallika Ghosh, Shobha Thangada, Oisharya Dasgupta, Kamal M. Khanna, Harold T. Yamase, Michael Kashgarian, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Supervision: Mallika Ghosh, Shobha Thangada, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Validation: Mallika Ghosh, Shobha Thangada, Kamal M. Khanna, Harold T. Yamase, Michael Kashgarian, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.
Visualization: Mallika Ghosh, Shobha Thangada, Kamal M. Khanna, Harold T. Yamase, Michael Kashgarian, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Writing – original draft: Mallika Ghosh, Shobha Thangada, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

Writing – review & editing: Mallika Ghosh, Shobha Thangada, Timothy Hla, Linda H. Shapiro, Fernando A. Ferrer.

References
1. Obinata H, Hla T. Fine-tuning S1P therapeutics. Chem Biol. 2012; 19(9):1080–2. Epub 2012/09/25. https://doi.org/10.1016/j.chembiol.2012.09.002 PMID: 22999874; PubMed Central PMCID: PMC3625427.

2. Bartels K, Grenz A, Eltzschig HK. Sphingosine-1-phosphate receptor signaling during acute kidney injury: the tissue is the issue. Kidney international. 2014; 85(4):733–5. Epub 2014/04/01. https://doi.org/10.1038/ki.2013.435 PMID: 24682118; PubMed Central PMCID: PMC4007344.

3. Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, Lynch KR, et al. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. The Biochemical journal. 2012; 447(1):149–57. Epub 2012/07/04. https://doi.org/10.1042/BJ20120609 PMID: 22747486; PubMed Central PMCID: PMC3443596.

4. Neubauer HA, Pitson SM. Roles, regulation and inhibitors of sphingosine kinase 2. Febs J. 2013; 280(21):5317–36. Epub 2013/05/04. https://doi.org/10.1111/febs.12314 PMID: 23638983.

5. Bajwa A, Jo SK, Ye H, Huang L, Dondeyi KR, Rosin DL, et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol. 2010; 21(6):955–65. Epub 2010/03/27. https://doi.org/10.1681/ASN.2009060662 PMID: 20338995; PubMed Central PMCID: PMC2900956.

6. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014; 510(7503):58–67. https://doi.org/10.1038/nature13475 PMID: 24899305; PubMed Central PMCID: PMC4320971.

7. Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, et al. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem. 2015; 58(4):1879–99. Epub 2015/02/03. https://doi.org/10.1021/jm501760d PMID: 25643074.

8. Bajwa A, Huang L, Kurmaeva E, Ye H, Dondeyi KR, Chrosicki P, et al. Sphingosine Kinase 2 Deficiency Attenuates Kidney Fibrosis via IFN-gamma. J Am Soc Nephrol. 2016. https://doi.org/10.1681/ASN.2016030306 PMID: 27749486.

9. Schwalm S, Beyer S, Frey H, Haceni R, Grammatikos G, Thomas D, et al. Sphingosine kinase-2 deficiency ameliorates kidney fibrosis by up-regulating Smad7 in a mouse model of unilateral ureteral obstruction. Am J Pathol. 2017. https://doi.org/10.1016/j.ajpath.2017.06.017 PMID: 28807595.

10. Masaki T, Foti R, Hill PA, Ikezumi Y, Atkins RC, Nikolic-Paterson DJ. Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney. Kidney international. 2003; 63(4):1256–64. Epub 2003/03/13. https://doi.org/10.1046/j.1523-1755.2003.00874.x PMID: 12631342.

11. Jablonski P, Howden BO, Rae DA, Birrell CS, Marshall VC, Tange J. An experimental model for assessment of renal recovery from warm ischemia. Transplantation. 1983; 35(3):198–204. Epub 1983/03/01. PMID: 6340272.

12. Thangada S, Shapiro LH, Silva C, Yamase H, Hla T, Ferrer FA. Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction. J Urol. 2014; 191(5 Suppl):1508–16. Epub 2014/04/01. https://doi.org/10.1016/j.juro.2013.07.072 PMID: 24679864.

13. Ghosh M, Subramani J, Rahman MM, Shapiro LH, CD13 Restricts TLR4 Endocytic Signal Transduction in Inflammation. Journal of immunology. 2015; 194(9):4466–76. Epub 2015/03/25. https://doi.org/10.4049/jimmunol.1403133 PMID: 25801433; PubMed Central PMCID: PMC4402264.

14. Ying W, Chenuku PS, Bazer FW, Safe SH, Zhou B. Investigation of macrophage polarization using bone marrow derived macrophages. Journal of visualized experiments JoVE. 2013;(76). Epub 2013/07/16. https://doi.org/10.3791/50323 PMID: 23851980.

15. Fujiu K, Manabe I, Nagai R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. The Journal of clinical investigation. 2011; 121(9):3425–41. Epub 2011/08/09. https://doi.org/10.1172/JCI57582 PMID: 21821915; PubMed Central PMCID: PMC3163964.

16. Davis MJ, Tsaung TM, Qiu Y, Dayrit JK, Freij JB, Huffnagle GB, et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoforms infection.
Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, et al. Suppression of ulcerative colitis in mice with ureteral obstruction. J Surg Res. 2015; 197(1):145–54. https://doi.org/10.1016/j.jss.2015.03.034 PMID: 25913488.

Kim D, Lee AS, Jung YJ, Yang KH, Lee S, Park SK, et al. Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor alpha-mediated transforming growth factor-beta1/Smad signaling pathway. Nephrol Dial Transplant. 2014; 29(11):2043–53. https://doi.org/10.1093/ndt/gfu240 PMID: 25031017.

Gross ML, Koch A, Muhlbauer B, Adamczak M, Ziebart H, Drescher K, et al. Renoprotective effect of an online tool to gauge safety-critical performance in radiation oncology. Practical radiation oncology. 2015; 5(2):127–34. Epub 2015/03/10. https://doi.org/10.1016/j.prro.2014.10.012 PMID: 25748005.

Netoli TA, Hussin H, Rogers KA, Smith LA, Wang B, Budman Y, et al. Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease. Hum Mol Genet. 2012; 21(15):3397–407. Epub 2012/05/09. https://doi.org/10.1093/hmg/dds172 PMID: 22563011; PubMed Central PMCID: PMC3684317.

Dunscombe P, Brown D, Donaldson H, Greener A, O'Neill M, Sutlief S, et al. Safety Profile Assessment: A novel sphingosine kinase inhibitor in experimental Crohn's disease. Inflammopharmacology. 2010; 18(2):73–85. Epub 2010/02/13. https://doi.org/10.1007/s10787-010-0032-x PMID: 20151210.
34. Fitzpatrick LR, Green C, Maines LW, Smith CD. Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2. Pharmacology. 2011; 87(3–4):135–43. Epub 2011/02/25. https://doi.org/10.1159/000323911 PMID: 21346391.

35. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005; 25(24):11113–21. Epub 2005/11/30. https://doi.org/10.1128/MCB.25.24.11113-11121.2005 PMID: 16314531; PubMed Central PMCID: PMC1316977.

36. Lai WQ, Irwan AW, Goh HH, Melendez AJ, McLnnes IB, Leung BP. Distinct roles of sphingosine kinase 1 and 2 in murine collagen-induced arthritis. J Immunol. 2009; 183(3):2097–103. https://doi.org/10.4049/jimmunol.0804376 PMID: 19596980.

37. Fitzpatrick LR, Green C, Frauenhoffer EE, French KJ, Zhuang S, Maines LW, et al. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology. 2011; 19(2):75–87. https://doi.org/10.1007/s10787-010-0060-6 PMID: 20936538.

38. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002; 13(10):2600–10. Epub 2002/09/20. PMID: 12239251.

39. Jang HS, Kim JI, Jung KJ, Kim J, Han KH, Park KM. Bone marrow-derived cells play a major role in kidney fibrosis via proliferation and differentiation in the infiltrated site. Biochimica et biophysica acta. 2013; 1832(6):817–25. Epub 2013/03/08. https://doi.org/10.1016/j.bbadis.2013.02.016 PMID: 23466592.

40. Tian S, Zhang L, Tang J, Guo X, Dong K, Chen SY. HMGBl exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury. Am J Physiol Renal Physiol. 2015; 308(1):F69–75. Epub 2014/11/08. https://doi.org/10.1152/ajprenal.00484.2014 PMID: 25377911; PubMed Central PMCID: PMC4281691.

41. Qin T, Du R, Huang F, Yin S, Yang J, Qin S, et al. Sinomenine activation of Nrf2 signaling prevents hyperactive inflammation and kidney injury in a mouse model of obstructive nephropathy. Free radical biology & medicine. 2016; 92:90–9. Epub 2016/01/23. https://doi.org/10.1016/j.freeradbiomed.2016.01.011 PMID: 26755999.

42. Susnik N, Sorensen-Zender I, Rong S, von Vlettinghoff S, Lu X, Rubera I, et al. Ablation of proximal tubular suppressor of cytokine signaling 3 enhances tubular cell cycling and modifies macrophage phenotype during acute kidney injury. Kidney Int. 2014; 85(6):1357–68. Epub 2014/01/10. https://doi.org/10.1038/kid.2013.525 PMID: 24402091.

43. Lech M, Grobmayr R, Ryu M, Lorenz G, Hartter I, Mulay SR, et al. Macrophage phenotype controls long-term AKI outcomes—kidney regeneration versus atrophy. J Am Soc Nephrol. 2014; 25(2):292–304. Epub 2013/12/07. https://doi.org/10.1615/ASN.2013020152 PMID: 24309188; PubMed Central PMCID: PMCPMC3904561.

44. Ranganathan PV, Jayakumar C, Ramesh G. Netrin-1-treated macrophages protect the kidney against ischemia-reperfusion injury and suppress inflammation by inducing M2 polarization. Am J Physiol Renal Physiol. 2013; 304(7):F948–57. Epub 2013/02/15. https://doi.org/10.1152/ajprenal.00580.2012 PMID: 23408164; PubMed Central PMCID: PMCPMC3625850.

45. Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, et al. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2011; 31(12):2856–64. Epub 2011/10/08. https://doi.org/10.1161/ATVBAHA.111.237198 PMID: 21979434; PubMed Central PMCID: PMC3227118.

46. Li C, Ding XY, Xiang DM, Xu J, Huang XL, Hou FF, et al. Enhanced M1 and Impaired M2 Macrophage Polarization and Reduced Mitochondrial Biogenesis via Inhibition of AMP Kinase in Chronic Kidney Disease. Cell Physiol Biochem. 2015; 36(1):358–72. https://doi.org/10.1159/000430106 PMID: 25967974.

47. Guiteras R, Flaquer M, Cruzado JM. Macrophage in chronic kidney disease. Clin Kidney J. 2016; 9 (6):765–71. https://doi.org/10.1093/ckj/sfw096 PMID: 27994852; PubMed Central PMCID: PMCPMC5162417.

48. Meng XM, Tang PM, Li J, Lan HY. Macrophage Phenotype in Kidney Injury and Repair. Kidney Dis (Basel). 2015; 1(2):138–46. https://doi.org/10.1159/000431214 PMID: 27536674; PubMed Central PMCID: PMCPMC4934816.

49. Kushiyama T, Oda T, Yamada M, Higashi K, Yamamoto K, Sakurai Y, et al. Alteration in the phenotype of macrophages in the repair of renal interstitial fibrosis in mice. Nephrology (Carlton). 2011; 19(2):75–87. https://doi.org/10.1111/j.1440-1797.2010.01439.x PMID: 21199156.

50. Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J Am Coll Cardiol. 2014; 63(15):1556–66. Epub 2013/12/24. https://doi.org/10.1016/j.jacc.2013.11.023 PMID: 24361318; PubMed Central PMCID: PMCPMC3992176.
infarction model. J Inflamm (Lond). 2015; 12:11. Epub 2015/02/17. https://doi.org/10.1186/s12950-015-0053-8 PMID: 25685072; PubMed Central PMCID: PMC4328069.

52. Yang N, Cheng W, Hu H, Xue M, Li X, Wang Y, et al. Atorvastatin attenuates sympathetic hyperinnervation together with the augmentation of M2 macrophages in rats postmyocardial infarction. Cardiovascular therapeutics. 2016; 34(4):234–44. Epub 2016/05/06. https://doi.org/10.1111/j.1755-5922.12193 PMID: 27149420.

53. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012; 18(7):1028–40. https://doi.org/10.1038/nm.2807 PMID: 22772564; PubMed Central PMCID: PMCPMC3405917.

54. Shivshankar P, Halade GV, Calhoun C, Escobar GP, Mehr AJ, Jimenez F, et al. Caveolin-1 deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice after myocardial infarction. J Mol Cell Cardiol. 2014; 76:84–93. Epub 2014/08/17. https://doi.org/10.1016/j.yjmcc.2014.07.020 PMID: 25128086; PubMed Central PMCID: PMC4533121.

55. Pan B, Liu G, Jiang Z, Zheng D. Regulation of renal fibrosis by macrophage polarization. Cell Physiol Biochem. 2015; 35(3):1062–9. https://doi.org/10.1159/000373932 PMID: 25662173.

56. Gharib SA, Johnston LK, Huizar I, Birkland TP, Hanson J, Wang Y, et al. MMP28 promotes macrophage polarization toward M2 cells and augments pulmonary fibrosis. J Leukoc Biol. 2014; 95(1):9–18. Epub 2013/08/22. https://doi.org/10.1189/jlb.1112587 PMID: 23964118; PubMed Central PMCID: PMCPMC3866192.

57. Gharib SA, Bench EM, Sussman SW, Wang RT, Rims C, et al. Tissue inhibitor of metalloproteinases-3 moderates the proinflammatory status of macrophages. Am J Respir Cell Mol Biol. 2013; 49(5):768–77. Epub 2013/06/08. 10.1165/rcmb.2012-0377OC. 23742180; PubMed Central PMCID: PMCPMC3865179.

58. Nahrendorf M, Swirski FK. Abandoning M1/M2 for a Network Model of Macrophage Function. Circ Res. 2016; 119(3):414–7. https://doi.org/10.1161/CIRCRESAHA.116.309194 PMID: 2719780; PubMed Central PMCID: PMCPMC4965179.

59. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014; 41(1):14–20. https://doi.org/10.1016/j.immuni.2014.06.008 PMID: 25035950; PubMed Central PMCID: PMC4123412.

60. Cao Q, Wang C, Zheng D, Wang Y, Lee VW, Wang YM, et al. IL-25 induces M2 macrophages and reduces renal injury in proteinuric kidney disease. J Am Soc Nephrol. 2011; 22(7):1229–39. Epub 2011/07/02. https://doi.org/10.1681/ASN.2010070693 PMID: 21719780; PubMed Central PMCID: PMC3137571.

61. Swaminathan S, Griffin MD. First responders: understanding monocyte-lineage traffic in the acutely injured kidney. Kidney international. 2008; 74(12):1509–11. Epub 2008/11/27. https://doi.org/10.1038/ki.2008.555 PMID: 19034300.

62. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13. Epub 2014/03/29. https://doi.org/10.12703/P6-13 PMID: 24669294; PubMed Central PMCID: PMC3944738.

63. Park SJ, Lee KP, Kang S, Lee J, Sato K, Chung HY, et al. Sphingosine 1-phosphate induced anti-atherogenic and atheroprotective M2 macrophage polarization through IL-4. Cell Signal. 2014; 26(10):2249–58. https://doi.org/10.1016/j.cellsig.2014.07.009 PMID: 25035231.

64. Weigert A, Schiffmann S, Sekar D, Ley S, Werno C, et al. Sphingosine Kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer. 2009; 125(9):2114–21. https://doi.org/10.1002/ijc.24594 PMID: 19618460.

65. Tannahill GM, Curtis AM, Palsson-McDermott EM, McGlade CF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature. 2013; 496(7444):238–42. https://doi.org/10.1038/nature12198 PMID: 23535595; PubMed Central PMCID: PMC4031686.
70. Lo TH, Tseng KY, Tsao WS, Yang CY, Hsieh SL, Chiu AW, et al. TREM-1 regulates macrophage polarization in ureteral obstruction. Kidney Int. 2014; 86(6):1174–86. Epub 2014/06/12. https://doi.org/10.1038/ki.2014.205 PMID: 24918157.

71. Lan R, Geng H, Singha PK, Saikumar P, Bottinger EP, Weinberg JM, et al. Mitochondrial Pathology and Glycolytic Shift during Proximal Tubule Atrophy after Ischemic AKI. J Am Soc Nephrol. 2016; 27(11):3356–67. https://doi.org/10.1681/ASN.20150202177 PMID: 27000065; PubMed Central PMCID: PMCPMC5084876.

72. Venkatachalal MA, Weinberg JM, Kriz W, Bidani AK. Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression. J Am Soc Nephrol. 2015; 26(8):1765–76. https://doi.org/10.1681/ASN.2015010006 PMID: 25810494; PubMed Central PMCID: PMCPMC4520181.

73. Zhao L, Zhang H, Yang Y, Zheng Y, Dong M, Wang Y, et al. Serum metabonomic analysis of protective effects of Curcuma aromatica oil on renal fibrosis rats. PLoS One. 2014; 9(9):e108678. https://doi.org/10.1371/journal.pone.0108678 PMID: 25265289; PubMed Central PMCID: PMCPMC4181651.

74. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007; 204(12):3037–47. Epub 2007/11/21. jem.20070885 [pii] https://doi.org/10.1084/jem.20070885 PMID: 18025128; PubMed Central PMCID: PMC2118517.

75. Geissmann F, Mass E. A stratified myeloid system, the challenge of understanding macrophage diversity. Semin Immunol. 2015; 27(6):353–6. https://doi.org/10.1016/j.smim.2016.03.016 PMID: 27038773; PubMed Central PMCID: PMCPMC4968038.

76. El Sabbahy M, Vaidya VS. Ischemic kidney injury and mechanisms of tissue repair. Wiley interdisciplinary reviews Systems biology and medicine. 2011; 3(5):606–18. Epub 2011/01/05. https://doi.org/10.1002/wsbm.133 PMID: 21197658; PubMed Central PMCID: PMCPMC3087860.

77. Van Raemdonck K, Van den Steen PE, Liekens S, Van Damme J, Struyf S. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev. 2015; 26(3):311–27. https://doi.org/10.1016/j.cytogfr.2014.11.009 PMID: 25498524.